Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease
CI Coleman, WL Baker, AK Meinecke… - European Heart …, 2020 - academic.oup.com
… or peripheral artery disease (PAD) treated in routine practice. … Compared with Vitamin
K Antagonism for Prevention of … This study was funded by Bayer AG, Berlin, Germany. The …
K Antagonism for Prevention of … This study was funded by Bayer AG, Berlin, Germany. The …
Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease
…, G Deray, J Floege, M Gwechenberger, K Hahn… - JACC: Advances, 2024 - jacc.org
… for both rivaroxaban and apixaban no significant risk … the effectiveness and safety of
rivaroxaban and VKA therapy when used in routine practice within the vulnerable group of patients …
rivaroxaban and VKA therapy when used in routine practice within the vulnerable group of patients …
Efficacy and safety of vitamin-K antagonists and direct oral anticoagulants for stroke prevention in patients with heart failure and sinus rhythm: An updated systematic …
W Li, J Seo, DG Kokkinidis… - … Journal of Stroke, 2023 - journals.sagepub.com
… stroke prevention in patients with atrial fibrillation (AF). Their … risk failed to influence clinical
practice and recommendations, as … of apixaban, with near-complete in-vivo FXIa inhibition, in …
practice and recommendations, as … of apixaban, with near-complete in-vivo FXIa inhibition, in …
The number of concomitant drugs and the safety of direct oral anticoagulants in routine care patients with atrial fibrillation
CJ van den Dries, S van Doorn, P Souverein… - TH Open, 2020 - thieme-connect.com
… (DOACs) versus vitamin K antagonists (VKAs) on major … -patients treated in routine practice.
The United Kingdom Clinical … comparing apixaban, rivaroxaban, and dabigatran to warfarin. …
The United Kingdom Clinical … comparing apixaban, rivaroxaban, and dabigatran to warfarin. …
Real-world comparison of direct-acting oral anticoagulants and vitamin K antagonists in chronic kidney disease: a systematic review and meta-analysis
R Xu, F Wu, J Lan, P Duan - Expert Review of Hematology, 2021 - Taylor & Francis
… between the patients treated in routine practice and the patients in … only warfarin or apixaban
for ESRD patients requiring … patients, the RENAL-AF trial, has indicated that apixaban …
for ESRD patients requiring … patients, the RENAL-AF trial, has indicated that apixaban …
Risk Profiles of New Users of Oral Anticoagulants Between 2011 and 2019 in Germany
A Voss, B Kollhorst, K Platzbecker, U Amann… - Clinical …, 2023 - Taylor & Francis
… (vitamin K antagonist) between 2011 and 2019 in Germany. … , apixaban or edoxaban, we
considered all patients with a first-… The data reflect routine clinical practice in Germany and they …
considered all patients with a first-… The data reflect routine clinical practice in Germany and they …
[HTML][HTML] Comparison of Effectiveness and Safety of Direct-Acting Oral Anticoagulants and Vitamin K Agonists in Patients With Atrial Fibrillation and End-Stage Kidney …
T Sinha, AH Mayow, TT Abedin, CN Phoo, SH Shawl… - Cureus, 2024 - ncbi.nlm.nih.gov
… , safe, and convenient alternative to vitamin K antagonists (… bleeding were noted in patients
treated with apixaban [9]. … mirror real-world practices regarding DOAC monitoring. Unlike …
treated with apixaban [9]. … mirror real-world practices regarding DOAC monitoring. Unlike …
Safety of direct oral anticoagulants in older adults with atrial fibrillation: a systematic review and meta-analysis of (subgroup analyses from) randomized controlled …
K Doni, S Bühn, A Weise, NK Mann, S Hess… - 2021 - researchsquare.com
… Vitamin K antagonists (VKA) have been the main treatment … We only included trials
published in English or German or … could be the different VKA prescribing practices; in the USA, …
published in English or German or … could be the different VKA prescribing practices; in the USA, …
Critical appraisal and issues regarding generalisability of comparative effectiveness studies of NOACs in atrial fibrillation and their relation to clinical trial data: a …
EM Bunge, B van Hout, S Haas, G Spentzouris… - BMJ open, 2021 - bmjopen.bmj.com
… Research Practices for comparative effectiveness research. … vitamin K antagonists (VKAs)
in patients with non-valvular … and apixaban in patients with non-valvular atrial fibrillation: a …
in patients with non-valvular … and apixaban in patients with non-valvular atrial fibrillation: a …
Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort
H Aebersold, F Foster-Witassek, S Aeschbacher… - Open …, 2024 - openheart.bmj.com
… -5D-3L valuation algorithms (German and French value sets … switching patients from VKA
to DOAC in clinical practice and … vitamin K antagonists in real-world patients with nonvalvular …
to DOAC in clinical practice and … vitamin K antagonists in real-world patients with nonvalvular …